55 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Biopharmaceutical
  • Chronic Disease
  • Pathology
  • Therapy

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • Therapy
  • Anergis SA
  • ALLERGEN FOR PEANUT ALLERGY - DRUG PROFILE
  • ALLERGEN FOR PEANUT ALLERGY - DRUG PROFILE

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • Chemotherapy
  • Therapy
  • Vaccine for Grass Pollen Allergy - Drug Profile
  • Vaccine for Grass Pollen Allergy - Drug Profile

Vaccine ## for Grass Pollen Allergy - Drug Profile Vaccine for Grass Pollen Allergy - Drug Profile Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Vaccine for Grass Pollen Allergy DC##U B

  • Allergy
  • Biopharmaceutical
  • Immunotherapy
  • United States
  • Product Initiative
  • Cedar Pollen Allergy - Drug Profiles
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Biopharmaceutical
  • Chemotherapy
  • Medical Biotechnology
  • Japan
  • Product Initiative
  • Vaccine for Grass Pollen Allergy - Drug Profile
  • Vaccine 1 for Grass Pollen Allergy - Drug Profile

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • United States
  • Product Initiative
  • BM-34 - Drug Profile
  • BM-34 - Drug Profile

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • Therapy
  • Biomay AG
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE
  • BM-34 - Drug Profile

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Biopharmaceutical
  • Chronic Disease
  • United States
  • Product Initiative
  • Cedar Pollen Allergy - Drug Profiles
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Biopharmaceutical
  • Chemotherapy
  • Pharmaceutical
  • Japan
  • Product Initiative
  • ALLERGEN FOR PEANUT ALLERGY - DRUG PROFILE
  • R&D Progress

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Biopharmaceutical
  • Chronic Disease
  • Therapy
  • Aimmune Therapeutics, Inc.
  • PL-103 - DRUG PROFILE

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • HIV AIDS
  • Therapy
  • PL-103 - DRUG PROFILE
  • AM-101 - DRUG PROFILE

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • HIV AIDS
  • Therapy

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy
  • Allergy Drug
  • Biopharmaceutical
  • Eye Disease
  • Ophthalmic Solution
  • Mechanism of Allergic Reaction

Drug Allergy- The allergy from medicines, drugs is the most common form of allergy.

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Biopharmaceutical
  • Medical Biotechnology
  • UB-221 - DRUG PROFILE
  • QBKPN-SSI - DRUG PROFILE

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Biopharmaceutical
  • Chemotherapy
  • HIV AIDS
  • Immunotherapy

The hypersensitivity of the body to sun rays causes sun allergy. ##. ## Types of Allergy by Allergens Drug Allergy-The allergy from medicines, drugs is the most common form of allergy.

  • Allergy Immunotherapy
  • Biopharmaceutical
  • World
  • Market Size
  • Allergy Therapeutics plc

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Biopharmaceutical
  • Blood Disease
  • Chemotherapy
  • HIV AIDS
  • Bristol-Myers Squibb Company

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Biopharmaceutical
  • Cancer
  • Chemotherapy
  • HIV AIDS
  • Bristol-Myers Squibb Company
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • MEPOLIZUMAB - DRUG PROFILE

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Biopharmaceutical
  • Chemotherapy
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • MEPOLIZUMAB - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Biopharmaceutical
  • Blood Disease
  • Chemotherapy
  • HIV AIDS
  • United States
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Biopharmaceutical
  • Chemotherapy
  • Digestive System Disorder
  • United States
  • Product Initiative

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy
  • Allergy Drug
  • Biopharmaceutical
  • Eye Disease
  • Ophthalmic Solution
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate is in Phase II stage for peanut allergy, grass pollen allergy, chronic urticaria, and dermatitis globally.

  • Biopharmaceutical
  • Chemotherapy
  • HIV AIDS
  • Monoclonal Antibody
  • Respiratory Disease

Hoffmann-La Roche Ltd ## ## ## ## ## AnaptysBio Inc ## ## ## ## ## Food Allergy Research & Education Inc ## ## ## ## ## Novartis AG ## ## ## ## ## Droege International Group AG ## ## ## ## ## Allertein Therapeutics LLC ## ## ## ## ## Allergy Therapeutics

  • Allergy
  • Allergy Immunotherapy
  • Biopharmaceutical
  • Chemotherapy
  • Clinical Trial
  • 7.4 STRATEGIES TO MINIMIZE SIDE EFFECTS IN IMMUNOTHERAPY PROTOCOLS

WORLD ALLERGY ORGANIZATION JOURNAL, ##(##), PP. ##-##.

  • Biopharmaceutical
  • HIV AIDS
  • World
  • Forecast
  • Aimmune Therapeutics, Inc.
  • MEPOLIZUMAB - DRUG PROFILE

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Biopharmaceutical
  • Chemotherapy
  • HIV AIDS
  • United States
  • Product Initiative

This was supported by the one-time other revenue of & euro## million recognized in February 2017 for out-licensing of the OTC-allergy drug Xyzal®(levoceterizine).

  • Biopharmaceutical
  • Medical Device
  • United States
  • Company Financials
  • UCB S.A.
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Biopharmaceutical
  • Chemotherapy
  • Therapy
  • Canada
  • United States
  • TRIALS THAT WILL FURTHER ASSESS TREATMENT OF SUBSEQUENT ASTHMA ATTACKS IN MEPOLIZUMAB-NAIVE AS WELL AS PREVIOUSLY-TREATED PATIENTS.
  • MEPOLIZUMAB - DRUG PROFILE

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Biopharmaceutical
  • Chemotherapy
  • HIV AIDS
  • United States
  • Product Initiative
  • Jun 06, 2017: Allergy Therapeutics: Directorate changes

He has previously spent over six years working at the US Food and Drug Administration (FDA) as a Medical Officer and Medical Team Leader in the Division of Pulmonary-Allergy Drug Products.

  • Biopharmaceutical
  • Europe
  • United States
  • Company Financials
  • Allergy Therapeutics plc